Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
2000 4
2001 1
2002 1
2003 2
2006 2
2015 1
2016 1
2017 1
2020 1
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).
Vavolizza RD, Petroni GR, Mauldin IS, Chianese-Bullock KA, Olson WC, Smith KT, Dengel LT, Haden K, Grosh WW, Kaur V, Varhegyi N, Gaughan EM, Slingluff CL Jr. Vavolizza RD, et al. Among authors: haden k. J Immunother Cancer. 2022 Sep;10(9):e005424. doi: 10.1136/jitc-2022-005424. J Immunother Cancer. 2022. PMID: 36100309 Free PMC article. Clinical Trial.
Mitochondrial Proteome Changes Correlating with β-Amyloid Accumulation.
Völgyi K, Háden K, Kis V, Gulyássy P, Badics K, Györffy BA, Simor A, Szabó Z, Janáky T, Drahos L, Dobolyi Á, Penke B, Juhász G, Kékesi KA. Völgyi K, et al. Among authors: haden k. Mol Neurobiol. 2017 Apr;54(3):2060-2078. doi: 10.1007/s12035-015-9682-4. Epub 2016 Feb 24. Mol Neurobiol. 2017. PMID: 26910821
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH, Obeng RC, Cummings KL, Petroni GR, Ambakhutwala AL, Chianese-Bullock KA, Smith KT, Lulu A, Varhegyi N, Smolkin ME, Myers P, Mahoney KE, Shabanowitz J, Buettner N, Hall EH, Haden K, Cobbold M, Hunt DF, Weiss G, Gaughan E, Slingluff CL Jr. Engelhard VH, et al. Among authors: haden k. J Immunother Cancer. 2020 May;8(1):e000262. doi: 10.1136/jitc-2019-000262. J Immunother Cancer. 2020. PMID: 32385144 Free PMC article. Clinical Trial.
1.2 Cognition and learning.
Falk-Nilsson E, Walmsley D, Brennan M, Fournier DM, Junfin Glass B, Haden K, Kersten H, Neumann L, Lian GO, Petersson K. Falk-Nilsson E, et al. Among authors: haden k. Eur J Dent Educ. 2002;6 Suppl 3:27-32. doi: 10.1034/j.1600-0579.6.s3.4.x. Eur J Dent Educ. 2002. PMID: 12390256
Dental education summits: the challenges ahead.
Bailit H, Weaver R, Haden K, Kotowicz W, Hovland E. Bailit H, et al. Among authors: haden k. J Am Dent Assoc. 2003 Aug;134(8):1109-13. doi: 10.14219/jada.archive.2003.0327. J Am Dent Assoc. 2003. PMID: 12956353
Synaptic mitochondria: a brain mitochondria cluster with a specific proteome.
Völgyi K, Gulyássy P, Háden K, Kis V, Badics K, Kékesi KA, Simor A, Györffy B, Tóth EA, Lubec G, Juhász G, Dobolyi A. Völgyi K, et al. Among authors: haden k. J Proteomics. 2015 Apr 29;120:142-57. doi: 10.1016/j.jprot.2015.03.005. Epub 2015 Mar 14. J Proteomics. 2015. PMID: 25782751
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma.
Patel SP, Petroni GR, Roszik J, Olson WC, Wages NA, Chianese-Bullock KA, Smolkin M, Varhegyi N, Gaughan E, Smith KT, Haden K, Hall EH, Gnjatic S, Hwu P, Slingluff CL. Patel SP, et al. Among authors: haden k. J Immunother Cancer. 2021 Aug;9(8):e003220. doi: 10.1136/jitc-2021-003220. J Immunother Cancer. 2021. PMID: 34413169 Free PMC article. Clinical Trial.
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).
Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Wages NA, Olson WC, Smith KT, Haden K, Dengel LT, Dickinson A, Reed C, Gaughan EM, Grosh WW, Kaur V, Varhegyi N, Smolkin M, Galeassi NV, Deacon D, Hall EH. Slingluff CL Jr, et al. Among authors: haden k. J Immunother Cancer. 2021 Jan;9(1):e000934. doi: 10.1136/jitc-2020-000934. J Immunother Cancer. 2021. PMID: 33479025 Free PMC article. Clinical Trial.
17 results